FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947995092> ?p ?o ?g. }

• W2947995092 endingPage "6204" @default.
• W2947995092 startingPage "6196" @default.
• W2947995092 abstract "Abstract Background Pancreatic cancer patients are at risk for venous thromboembolism (VTE); the value of thromboprophylaxis has not been definitively established. Methods This trial randomized cancer patients initiating a new regimen and at high risk for VTE (Khorana score ≥2) to rivaroxaban 10 mg or placebo up to day 180. This analysis examined the subset of pancreatic cancer patients. The primary efficacy endpoint was the composite of symptomatic deep‐vein thrombosis (DVT), asymptomatic proximal DVT, any pulmonary embolism, and VTE‐related death. The primary safety endpoint was International Society on Thrombosis and Haemostasis–defined major bleeding. Results In total, 49/1080 (4.5%) patients enrolled had baseline VTE on screening, with higher rates (24/362 [6.6%]) in pancreatic cancer and they were not randomized. Of 841 randomized patients, 273 (32.5%) had pancreatic cancer; 155/273 (57% in each arm) completed the double‐blind period. The primary endpoint occurred in 13/135 (9.6%) patients in the rivaroxaban group and in 18/138 (13.0%) in the placebo group (hazard ratio [HR] = 0.70; 95% CI, 0.34‐1.43; P = .328) in up‐to‐day‐180 period and 5/135 (3.7%) patients receiving rivaroxaban and 14/138 (10.1%) receiving placebo in the intervention period (HR = 0.35; 95% CI, 0.13‐0.97; P = .034). Major bleeding was similar (2 [1.5%] receiving rivaroxaban and 3 [2.3%] receiving placebo). Correlative biomarker studies demonstrated significant decline in D‐dimer (weeks 8 and 16) in patients randomized to rivaroxaban compared to placebo ( P < .01). Conclusions In ambulatory pancreatic cancer patients, rivaroxaban did not result in significantly lower incidence of VTE or VTE‐related death in the 180‐day period. During the intervention period, however, rivaroxaban substantially reduced VTE without increasing major bleeding, suggesting benefit of rivaroxaban prophylaxis in this setting. Trial registration: ClinicalTrials.gov identifier, NCT02555878." @default.
• W2947995092 created "2019-06-07" @default.
• W2947995092 creator A5003827387 @default.
• W2947995092 creator A5009177808 @default.
• W2947995092 creator A5015917994 @default.
• W2947995092 creator A5026752543 @default.
• W2947995092 creator A5027772602 @default.
• W2947995092 creator A5028874800 @default.
• W2947995092 creator A5039576853 @default.
• W2947995092 creator A5041768679 @default.
• W2947995092 creator A5062083405 @default.
• W2947995092 creator A5076438320 @default.
• W2947995092 creator A5082506728 @default.
• W2947995092 date "2020-07-14" @default.
• W2947995092 modified "2023-09-30" @default.
• W2947995092 title "Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre‐specified subgroup analysis of the randomized CASSINI study" @default.
• W2947995092 cites W1589295587 @default.
• W2947995092 cites W1996600303 @default.
• W2947995092 cites W2031799746 @default.
• W2947995092 cites W2041113507 @default.
• W2947995092 cites W2054324054 @default.
• W2947995092 cites W2070441776 @default.
• W2947995092 cites W2093389482 @default.
• W2947995092 cites W2118362445 @default.
• W2947995092 cites W2137283681 @default.
• W2947995092 cites W2167494200 @default.
• W2947995092 cites W2316619083 @default.
• W2947995092 cites W2331598353 @default.
• W2947995092 cites W2587346638 @default.
• W2947995092 cites W2756343794 @default.
• W2947995092 cites W2759791460 @default.
• W2947995092 cites W2917722773 @default.
• W2947995092 cites W2980266010 @default.
• W2947995092 doi "https://doi.org/10.1002/cam4.3269" @default.
• W2947995092 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7476843" @default.
• W2947995092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32663379" @default.
• W2947995092 hasPublicationYear "2020" @default.
• W2947995092 type Work @default.
• W2947995092 sameAs 2947995092 @default.
• W2947995092 citedByCount "18" @default.
• W2947995092 countsByYear W29479950922020 @default.
• W2947995092 countsByYear W29479950922021 @default.
• W2947995092 countsByYear W29479950922022 @default.
• W2947995092 countsByYear W29479950922023 @default.
• W2947995092 crossrefType "journal-article" @default.
• W2947995092 hasAuthorship W2947995092A5003827387 @default.
• W2947995092 hasAuthorship W2947995092A5009177808 @default.
• W2947995092 hasAuthorship W2947995092A5015917994 @default.
• W2947995092 hasAuthorship W2947995092A5026752543 @default.
• W2947995092 hasAuthorship W2947995092A5027772602 @default.
• W2947995092 hasAuthorship W2947995092A5028874800 @default.
• W2947995092 hasAuthorship W2947995092A5039576853 @default.
• W2947995092 hasAuthorship W2947995092A5041768679 @default.
• W2947995092 hasAuthorship W2947995092A5062083405 @default.
• W2947995092 hasAuthorship W2947995092A5076438320 @default.
• W2947995092 hasAuthorship W2947995092A5082506728 @default.
• W2947995092 hasBestOaLocation W29479950921 @default.
• W2947995092 hasConcept C121608353 @default.
• W2947995092 hasConcept C126322002 @default.
• W2947995092 hasConcept C141071460 @default.
• W2947995092 hasConcept C142724271 @default.
• W2947995092 hasConcept C168563851 @default.
• W2947995092 hasConcept C203092338 @default.
• W2947995092 hasConcept C204787440 @default.
• W2947995092 hasConcept C207103383 @default.
• W2947995092 hasConcept C27081682 @default.
• W2947995092 hasConcept C2776265017 @default.
• W2947995092 hasConcept C2776301958 @default.
• W2947995092 hasConcept C2778661090 @default.
• W2947995092 hasConcept C2778959117 @default.
• W2947995092 hasConcept C2779161974 @default.
• W2947995092 hasConcept C2780210213 @default.
• W2947995092 hasConcept C2780868729 @default.
• W2947995092 hasConcept C2781413609 @default.
• W2947995092 hasConcept C44249647 @default.
• W2947995092 hasConcept C71924100 @default.
• W2947995092 hasConcept C90924648 @default.
• W2947995092 hasConceptScore W2947995092C121608353 @default.
• W2947995092 hasConceptScore W2947995092C126322002 @default.
• W2947995092 hasConceptScore W2947995092C141071460 @default.
• W2947995092 hasConceptScore W2947995092C142724271 @default.
• W2947995092 hasConceptScore W2947995092C168563851 @default.
• W2947995092 hasConceptScore W2947995092C203092338 @default.
• W2947995092 hasConceptScore W2947995092C204787440 @default.
• W2947995092 hasConceptScore W2947995092C207103383 @default.
• W2947995092 hasConceptScore W2947995092C27081682 @default.
• W2947995092 hasConceptScore W2947995092C2776265017 @default.
• W2947995092 hasConceptScore W2947995092C2776301958 @default.
• W2947995092 hasConceptScore W2947995092C2778661090 @default.
• W2947995092 hasConceptScore W2947995092C2778959117 @default.
• W2947995092 hasConceptScore W2947995092C2779161974 @default.
• W2947995092 hasConceptScore W2947995092C2780210213 @default.
• W2947995092 hasConceptScore W2947995092C2780868729 @default.
• W2947995092 hasConceptScore W2947995092C2781413609 @default.
• W2947995092 hasConceptScore W2947995092C44249647 @default.
• W2947995092 hasConceptScore W2947995092C71924100 @default.
• W2947995092 hasConceptScore W2947995092C90924648 @default.
• W2947995092 hasFunder F4320307771 @default.

• next